We are a clinical-stage pharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Our initial focus is on developing our novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) therapies for the treatment of patients with treatment-resistant-depression (TRD).

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where 87.5% of patients with TRD were brought into an ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has potential to change the way TRD is treated today.

Our portfolio also includes GH002 and GH003, our proprietary intravenous and intranasal 5-MeO-DMT product candidates.

SEC Filings